Page 208 - 2019_05-HaematologicaMondo-web

S. Delignat et al.
S, Takahashi Y. Unique properties of memo-
ry B cells of different isotypes. Immunol Rev.
2010;237(1):104–116.
14. Khan WN, Alt FW, Gerstein RM, et al.
Defective B cell development and function in Btk-deficient mice. Immunity. 1995;3(3): 283–299.
15. Di Paolo JA, Huang T, Balazs M, et al. Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis. Nat Chem Biol. 2011;7(1):41–50.
16. Honigberg LA, Smith AM, Sirisawad M, et al. The Bruton tyrosine kinase inhibitor PCI- 32765 blocks B-cell activation and is effica- cious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci U S A. 2010;107(29):13075–13080.
17. Hendriks RW, Yuvaraj S, Kil LP. Targeting Bruton’s tyrosine kinase in B cell malignan- cies. Nat Rev Cancer. 2014;14(4):219–232.
18. Rankin AL, Seth N, Keegan S, et al. Selective inhibition of BTK prevents murine lupus and antibody-mediated glomerulonephritis. J Immunol. 2013;191(9):4540–4550.
19. Benson MJ, Rodriguez V, von Schack D, et al. Modeling the clinical phenotype of BTK inhibition in the mature murine immune system. J Immunol. 2014;193(1):185–197.
20. Dumont JA, Liu T, Low SC, et al. Prolonged activity of a recombinant factor VIII-Fc fusion protein in hemophilia A mice and dogs. Blood. 2012;119(13):3024–3030.
21. Delignat S, Dasgupta S, André S, et al. Comparison of the immunogenicity of differ- ent therapeutic preparations of human factor VIII in the murine model of hemophilia A. Haematologica. 2007;92(10):1423–1426.
22. Dimitrov JD, Dasgupta S, Navarrete A-M, et al. Induction of heme oxygenase-1 in factor VIII-deficient mice reduces the immune response to therapeutic factor VIII. Blood. 2010;115(13):2682–2685.
23. Hausl C, Ahmad RU, Schwarz HP, et al. Preventing restimulation of memory B cells in hemophilia A: a potential new strategy for the treatment of antibody-dependent immune disorders. Blood. 2004;104(1):115– 122.
24. Delignat S, Repessé Y, Gilardin L, et al. Predictive immunogenicity of Refacto AF. Haemophilia. 2014;20(4):486–492.
25. Nutt SL, Hodgkin PD, Tarlinton DM, Corcoran LM. The generation of antibody-
secreting plasma cells. Nat Rev Immunol.
2015;15(3):160–171.
26. Meeks SL, Cox CL, Healey JF, et al. A major
determinant of the immunogenicity of fac- tor VIII in a murine model is independent of its procoagulant function. Blood. 2012;120 (12):2512–2520.
27. Wroblewska A, van Haren SD, Herczenik E, et al. Modification of an exposed loop in the C1 domain reduces immune responses to factor VIII in hemophilia A mice. Blood. 2012;119(22):5294–5300.
28. Mahévas M, Michel M, Weill J-C, Reynaud C-A. Long-lived plasma cells in autoimmu- nity: lessons from B-cell depleting therapy. Front Immunol. 2013; 4:494.
29. Meslier Y, André S, Dimitrov JD, et al. Bortezomib delays the onset of factor VIII inhibitors in experimental hemophilia A, but fails to eliminate established anti-factor VIII IgG-producing cells. J Thromb Haemost. 2011;9(4):719–728.
30. Liu CL, Lyle MJ, Shin SC, Miao CH. Strategies to target long-lived plasma cells for treating hemophilia A inhibitors. Cell Immunol. 2016;30165–30173.
31. Qian J, Collins M, Sharpe AH, Hoyer LW. Prevention and treatment of factor VIII inhibitors in murine hemophilia A. Blood. 2000;95(4):1324–1329.
32. Herman SEM, Gordon AL, Hertlein E, et al. Bruton tyrosine kinase represents a promis- ing therapeutic target for treatment of chronic lymphocytic leukemia and is effec- tively targeted by PCI-32765. Blood. 2011;117(23):6287–6296.
33. Navarrete A, Dasgupta S, Delignat S, et al. Splenic marginal zone antigen-presenting cells are critical for the primary allo-immune response to therapeutic factor VIII in hemo- philia A. J Thromb Haemost. 2009;7(11): 1816–1823.
34. Lai JD, Cartier D, Hartholt RB, et al. Early cellular interactions and immune transcrip- tome profiles in human factor VIII-exposed hemophilia A mice. J Thromb Haemost. 2018;16(3):533-545.
35. Kraal G, Mebius R. New insights into the cell biology of the marginal zone of the spleen. In: International Review of Cytology. Academic Press; p175–215.
36. Rossi G, Sarkar J, Scandella D. Long-term induction of immune tolerance after block-
ade of CD40-CD40L interaction in a mouse model of hemophilia A. Blood. 2001;97(9): 2750–2757.
37. Reipert BM, Sasgary M, Ahmad RU, Auer W, Turecek PL, Schwarz HP. Blockade of CD40/CD40 ligand interactions prevents induction of factor VIII inhibitors in hemo- philic mice but does not induce lasting immune tolerance. Thromb Haemost. 2001;86(6):1345–1352.
38. Smith CI, Baskin B, Humire-Greiff P, et al. Expression of Bruton’s agammaglobuline- mia tyrosine kinase gene, BTK, is selectively down-regulated in T lymphocytes and plas- ma cells. J Immunol. 1994;152(2):557–565.
39. Meslier Y, André S, Teyssandier M, Kaveri SV, Lacroix-Desmazes S. Maternally trans- ferred anti-factor VIII IgG reduce the anti- factor VIII humoral immune response in fac- tor VIII-deficient mice. Immunology. 2010;131(4):549–555.
40. Hartholt RB, Wroblewska A, Herczenik E, et al. Enhanced uptake of blood coagulation factor VIII containing immune complexes by antigen presenting cells. J Thromb Haemost. 2017;15(2):329–340.
41. Jacquemin MG, Desqueper BG, Benhida A, et al. Mechanism and kinetics of factor VIII inactivation: study with an IgG4 monoclon- al antibody derived from a hemophilia A patient with inhibitor. Blood. 1998;92(2): 496–506.
42. Jacquemin M, Benhida A, Peerlinck K, et al. A human antibody directed to the factor VIII C1 domain inhibits factor VIII cofactor activity and binding to von Willebrand fac- tor. Blood. 2000;95(1):156–163.
43. Moreau A, Lacroix-Desmazes S, Stieltjes N, et al. Antibodies to the FVIII light chain that neutralize FVIII procoagulant activity are present in plasma of nonresponder patients with severe hemophilia A and in normal polyclonal human IgG. Blood. 2000;95(11): 3435–3441.
44. Macauley MS, Pfrengle F, Rademacher C, et al. Antigenic liposomes displaying CD22 lig- ands induce antigen-specific B cell apopto- sis. J Clin Invest. 2013;123(7):3074–3083.
45. Hay CRM, DiMichele DM, International Immune Tolerance Study. The principal results of the International Immune Tolerance Study: a randomized dose com- parison. Blood. 2012;119(6):1335–1344.
1054
haematologica | 2019; 104(5)